Literature DB >> 9686956

Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine.

E H Garin1, P Laflam, L Chandler.   

Abstract

Supernatant factor from peripheral blood mononuclear cell (PBMC) cultures of idiopathic minimal lesion nephrotic syndrome (IMLNS) patients in relapse induces in vivo albuminuria and increases 35sulfate uptake by glomerular basement membrane (GBM) in rats. The purpose of this study was to evaluate the effect of anti-interleukin 8 (IL8) neutralizing antibody on the effects induced by the supernatant factor. Supernatant factor collected from six cultures of PBMC from IMLNS patients in relapse were combined and aliquotted into two samples. Anti-IL8 neutralizing antibody (750 ng) was added to one. Supernatant factor or supernatant factor and anti-IL8 antibody were infused for 5 days into the left renal artery of Wistar rats using an osmotic pump. On the last day of infusion, rats were injected with 35sulfate (1.0 mCi/200 g) intraperitoneally and killed after 8 h. Glomeruli were isolated and GBM obtained. There was a significant increase in 35sulfate uptake of the infused kidney (169 +/- 52 cpm/mg dry glomerular weight, mean +/- SEM) compared with the uptake seen in the contralateral kidney (116 +/- 41, P < 0.05) when the supernatant factor was infused alone. No significant differences in 35sulfate incorporation were seen between infused kidney (173 +/- 5) and contralateral kidney (190 +/- 49) when supernatant factor and anti-IL8 antibody were administered. A significant increase in albuminuria was seen on the last day of infusion (0.43 +/- 0.11 albumin/ creatinine ratio, mean +/- SEM) compared with the ratio prior to infusion of the supernatant factor alone (0.18 +/- 0.03, P <0.05). No significant differences in urinary albumin/creatinine ratios prior to and on the 5th day of infusion were seen when the supernatant factor was administered with anti-IL8 antibody. Supernatant factor effects were abolished by the addition of anti-IL8 neutralizing antibody, suggesting that the described effects are mediated by IL8.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9686956     DOI: 10.1007/s004670050470

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  Ask the expert. Does antibody induction therapy with daclizumab or basiliximab increase the risk of recurrence of post-transplant focal segmental glomerulosclerosis?

Authors:  Marie-France Gagnadoux
Journal:  Pediatr Nephrol       Date:  2002-04       Impact factor: 3.714

Review 2.  The role of the immune system in idiopathic nephrotic syndrome: a review of clinical and experimental studies.

Authors:  Wagner de Fátima Pereira; Gustavo Eustáquio Alvim Brito-Melo; Fábio Tadeu Lourenço Guimarães; Thiago Guimarães Rosa Carvalho; Elvis Cueva Mateo; Ana Cristina Simões e Silva
Journal:  Inflamm Res       Date:  2014-01       Impact factor: 4.575

3.  Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.

Authors:  Rodney D Gilbert; Eleanor Hulse; Susan Rigden
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 4.  Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.

Authors:  Gabriel Cara-Fuentes; William L Clapp; Richard J Johnson; Eduardo H Garin
Journal:  Pediatr Nephrol       Date:  2016-07-06       Impact factor: 3.714

Review 5.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

6.  Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome.

Authors:  Shipra Agrawal; Michael E Brier; Bryce A Kerlin; William E Smoyer
Journal:  Kidney Int Rep       Date:  2021-01-06

Review 7.  The Role of Cytokines in Nephrotic Syndrome.

Authors:  Elham Ahmadian; Yalda Rahbar Saadat; Elaheh Dalir Abdolahinia; Milad Bastami; Mohammadali M Shoja; Sepideh Zununi Vahed; Mohammadreza Ardalan
Journal:  Mediators Inflamm       Date:  2022-02-09       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.